

Empower Clinics Inc.

09:37 18 Apr 2019

Empower Clinics and Cannvas MedTech launch program to educate patients on alternative CBD therapies

Empower Clinics Inc (CSE:CBDT) (OTCMKTS:EPWCF) is partnering with a leading digital cannabis analytics company to place educational kiosks in each of its clinics to provide information, data and analysis of physician-recommended alternative CBD therapies.

Together with its partner, Cannvas MedTech Inc (CSE:MTEC) (OTCMKTS:CANVF), Empower is initiating a pilot program to launch a comprehensive education, data collection and analysis program that sees Cannvas kiosks installed in Empower's medical clinics.

READ: Empower Clinics plans to change name to CBD Therapeutics
The new partnership comes as Empower repositions its overall strategy to become a vertically integrated health and wellness company that connects to its 120,000 patients using a data-driven focus to improve patients' lives with products, technology and health systems, CEO Steven McAuley said in a statement.

"The addition of the Cannvas educational kiosks, a user friendly and highly interactive education platform, is a tremendous step forward to making our brand one of the go-to sources for content for both patients and the medical community nationwide," he said.

Cannvas' CEO Shawn Moniz said that the partnership represents an opportunity to bring unbiased cannabis education to a large population of patients looking for therapies to alleviate a number of ailments, while also learning more about what behaviours may drive the decision to look at cannabis as an alternative or complementary treatment.

Cannvas will be a key data and analytics partner for Empower by providing insights on customer behaviours and industry trends and integrating existing data partnerships.

Empower also plans to begin further pilot initiatives with Cannvas to provide content and educational links to Cannvas.me and Cannvas.health directly from the new Empower website www.empowerclinics.com and through its tele-medicine portal.

Shares of Empower closed Wednesday at C\$0.17 in Canada and US\$0.14 in the US, while Cannvas shares were at C\$0.26 in Canada and US\$0.19 in the US.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: C\$0.1

Market Cap: C\$7712110M

Share Information

Code: CBDT

Listing: CSE

52 week **High** **Low**
C\$0.35 C\$0.07

Sector: Cannabis [T3]

Website: www.empowerclinics.com

Company Synopsis:

Empower Inc. is a growing network of physician-staffed health clinics focused on helping patients improve and protect their health. Our mission is centered around physician-guided treatment for the relief of chemo-therapy side-effects, seizures, PTSD, and a multitude of chronic pain conditions.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.